SERVIER Laboratories (Australia) Pty Ltd Servier was eligible to receive $7 million in P3 funding; can you tell us how this initiative has helped the company? P3 was not one of the main reasons why Servier has invested more in Australia of late. What drives Servier’s headquarters to conduct more research in Australia is a…
Solvay Australia How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1 price cut at this stage. Nevertheless, there are two other drugs fully affected by the cut (-25%). This of course…
Stiefel Laboratories Pty Limited What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although that doesn’t preclude the company from having products on it in the future, there is no immediate effect or detriment to Stiefel due to the…
Bayer Australia Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines in the industry. In Australia, the company is launching in the next three years, 18 new products or product line…
Pharmaceutical Benefits Advisory Committee To begin, would you please give a brief introduction to the PBAC? The PBAC is a statutory committee of government first developed in Australia in the 1940s, which advises the Ministry of Health and Ageing as to what drugs will be listed on the Pharmaceutical Benefits Scheme (PBS). The Minister…
Government of Australia The Ministry for Innovation, Industry, Science and Research was created in December 2007 with the election of the Labor government. To begin, would you please give a brief introduction to the ministry and highlight its most significant achievements and milestones in this relatively short period of time? The whole point…
Pierre Fabre Australia Would you please introduce Pierre Fabre to our readers? Pierre Fabre Medicament Australia Pty Limited was established in Australia in late 2001, and is a fully owned subsidiary of the international parent company Pierre Fabre Medicament. Within Pierre Fabre Medicament, there are various divisions, of which oncology is among the…
Datapharm Australia Pty Ltd The Australian pharmaceutical sector has seen recent innovations through PBS reform and various working groups shaping the future of the industry. Can you comment on how Datapharm is reacting to these opportunities? Datapharm has actually put in a submission to the review of the National Innovation System, highlighting that innovation…
Genzyme Australia What impact will the recent PBS reforms have on Genzyme’s operations in Australia? Genzyme is different in terms of its focus on rare & unmet medical needs, so most of the company’s products, given they are targeted therapies, are not reimbursed through the PBS, but through other government funding mechanisms.…
Argentina SA Baxter Do you think this is a good moment for the Argentinean pharmaceutical industry to have international exposure? Indeed it is attractive, but we should keep the long term objectives on perspective. It is a stable and interesting market for multinational companies, as long as they can grasp the dynamics of…
Laboratorios Richmond What have been the recent major milestones for Richmond? One of the milestones for Laboratorios Richmond was to have developed the first branded oncological generic in the world. For Laboratorios Richmond to be developing combinations of different molecules from different originator laboratories is very important as well, as it provides…
Sayenko Kharenko If you could provide our readers with your philosophy when you founded Sayenko Kharenko in 2004. What were the market needs that were perhaps missing that you identified and wanted to address? If you look at the top 5 law firms in Ukraine, Sayenko Kharenko definitely is not the oldest…
See our Cookie Privacy Policy Here